Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
Abstract Background and aims When patients with sickle cell disease have appropriate indications, they can be prescribed hydroxyurea (HU) and deferasirox (DFX) concurrently despite little knowledge about how the two medications interact. We wished to analyze whether there was evidence of adverse int...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Health Science Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/hsr2.323 |